<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668924</url>
  </required_header>
  <id_info>
    <org_study_id>PIXLKC-II</org_study_id>
    <nct_id>NCT04668924</nct_id>
  </id_info>
  <brief_title>Epi-on PiXL for the Treatment of Progressive Keratoconus.</brief_title>
  <official_title>Prospective Evaluation of Photorefractive Intrastromal Crosslinking (PiXL) Without Epithelium Debridement (Epi-on) in High Oxygen for Progressive Keratoconus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and postoperative ocular&#xD;
      discomfort by individually customized Photorefractive intrastromal crosslinking (PiXL)&#xD;
      without epithelium debridement in high oxygen environment (Epi-on) for progressive&#xD;
      Keratoconus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a prospective, open-label, nonrandomized trial involving&#xD;
      participants of both genders aged 18-35 years with Keratoconus planned for routine corneal&#xD;
      crosslinking at the Department of Ophthalmology, Umeå University Hospital, Umeå, Sweden.&#xD;
&#xD;
      The study includes 30 participants with unilateral Keratoconus, receiving Epi-on PiXL in high&#xD;
      oxygen environment (n=30). All patients are informed about the procedures before consenting&#xD;
      to participate in the study.&#xD;
&#xD;
      At baseline, before treatment, each eye is examined with slit-lamp microscopy, subjective&#xD;
      refraction, determination of uncorrected (UCVA), low contrast visual acuity at 2.5 percentage&#xD;
      contrast and 10 percentage contrast and best corrected (BSCVA) visual acuities using the&#xD;
      LogMAR fast protocol and intraocular pressure (IOP) using Goldmann applanation tonometry.&#xD;
      Under standardized, mesopic light conditions each eye is evaluated by keratometry readings&#xD;
      and central corneal thickness, extracted from Schemipflug camera measurements, Pentacam HR®&#xD;
      (Oculus, Inc. Lynnwood, WA) and AS-OCT (Fourier domain OCT CASIA2, Tomey Technology and&#xD;
      vision, Germany).&#xD;
&#xD;
      Central corneal endothelial photographs are taken with the Topcon SP-IP specular microscope&#xD;
      (Topcon Europe B.V., Capelle a/d Ijssel, the Netherlands) and total ocular wavefront is&#xD;
      measured with iTrace (Tracey Technologies, Inc.).&#xD;
&#xD;
      Ocular discomfort is subjectively evaluated in each eye by a specific visual analogous rating&#xD;
      scale at 4h, 8h, 12h, 24h and thereafter daily up to 1 week postoperatively.&#xD;
&#xD;
      All the above mentioned examinations are repeated at 1, 3, 6, 12 and 24 months after&#xD;
      treatment. At 1 day and 1 week after treatment, solely UCVA, Auto refractor measurements,&#xD;
      slit-lamp examination are evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uncorrected Distance Visual Acuity (UDVA)</measure>
    <time_frame>1, 3, 6, 12 and 24 months after treatment.</time_frame>
    <description>Change from baseline in Uncorrected Distance Visual Acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Keratometry readings</measure>
    <time_frame>1, 3, 6, 12 and 24 months after treatment</time_frame>
    <description>Change from baseline in Keratometry readings, Kmean (average), K1 (flat meridian), K2 (steep meridian) and Kmax (steepest radius of curvature) assessed with the Pentacam HR Scheimpflug camera</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Ocular Discomfort Scores</measure>
    <time_frame>4, 8h and 1, 2, 3, 4, 5, 6 and 7 days after treatment.</time_frame>
    <description>Change in a Ocular Discomfort Visual Analogous Scale after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manifest Refractive Spherical Equivalent (MRSE)</measure>
    <time_frame>1, 3, 6, 12 and 24 months after treatment.</time_frame>
    <description>Change from baseline in Manifest Refractive Spherical Equivalent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Endothelial cell density (ECC)</measure>
    <time_frame>12 and 24 months after treatment</time_frame>
    <description>Change from baseline in corneal endothelial cell density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle Distance Visual Acutiy (BSCVA)</measure>
    <time_frame>1, 3, 6, 12 and 24 months after treatment.</time_frame>
    <description>Change from baseline in Best Spectacle Distance Visual Acutiy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Keratoconus</condition>
  <condition>Corneal Crosslinking</condition>
  <condition>Corneal Densitometry</condition>
  <condition>Scheimpflug Photography</condition>
  <condition>Corneal Disorder</condition>
  <condition>Eye Diseases</condition>
  <arm_group>
    <arm_group_label>Epi-on PiXL in high oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Photorefractive intrastromal corneal crosslinking without epithelium debridement during humidified high oxygen flow.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Epi-on PiXL in high oxygen</intervention_name>
    <description>After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for &lt; 45 Diopters (D) 7.2J/cm^2 will be used; for 45-50D 10J/cm^2 will be used; for &gt; 50D 15 J/cm^2 will be used.</description>
    <arm_group_label>Epi-on PiXL in high oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients planned for corneal crosslinking.&#xD;
&#xD;
          -  Progressive keratoconus documented with a consistent decrease of best corrected visual&#xD;
             acuity with no other explanation, an unquestionable historical progression, or a&#xD;
             progression documented with the Pentacam Scheimpflug camera with at least 2 of the&#xD;
             following: progressive anterior and/or posterior corneal steepening and/or progressive&#xD;
             corneal thinning and/or increased rate of corneal thickness change from the periphery&#xD;
             to the center.&#xD;
&#xD;
          -  A keratoconus diagnosis based on abnormal posterior elevation, abnormal corneal&#xD;
             thickness distribution and clinical noninflammatory corneal thinning using the&#xD;
             &quot;Belin/Ambrósio enhanced ectasia&quot; measurements of the Pentacam Scheimpflug camera.&#xD;
&#xD;
          -  Minimum corneal thickness of 400 µm at the thinnest point before epithelial removal.&#xD;
&#xD;
          -  18-35 years of age&#xD;
&#xD;
          -  No ocular abnormalities except keratoconus&#xD;
&#xD;
          -  No previous ocular surgery&#xD;
&#xD;
          -  No cognitive insufficiency interfering with the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18 or over 35&#xD;
&#xD;
          -  Any corneal abnormalities except keratoconus&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Previous ocular surgery&#xD;
&#xD;
          -  Cognitive insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Behndig</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Sciences/Ophthalmology, Umeå University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders Behndig, MD, PhD</last_name>
    <phone>+46707827536</phone>
    <email>anders.behndig@umu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sofie Näslund</last_name>
    <email>sofie.naslund@umu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Behndig, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

